GLP-1 R agonists, which exploit the physiological impacts of GLP-1, assert its impacts by potently reducing glucose level and disposing part of the pathophysiological features of type 2 diabetes, a progressive and multifaceted disease [22]. This evidence concerns the gene GCG and type 2 diabetes mellitus.